Akèy › Myelom Miltip › Connecticut › New Haven
Etid klinik pou Myelom Miltip nan New Haven, CT
14 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote New Haven (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Ap rekriteFaz 3
- Research Site, New Haven
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Ap rekriteFaz 2
- Yale University School Of Medicine, New Haven
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 3
- Yale Cancer Center, New Haven
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Ap rekriteFaz 3
- Yale New Haven Hospital, New Haven
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi lwen
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi lwen
- ak 1 plis
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Ap rekriteFaz 1/2
- Smilow Cancer Center At Yale-New Haven /ID# 272447, New Haven
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Ap rekriteFaz 3
- Yale University, New Haven
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Ap rekriteFaz 1/2
- Yale New Haven Hospital-Smilow Cancer Center, New Haven
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Ap rekriteFaz 3
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
- Smilow Cancer Hospital-Orange Care Center, Orange · 5 mi lwen
- ak 3 plis
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Ap rekriteFaz 3
- Research Site, New Haven
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Ap rekriteFaz 3
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi lwen
- ak 2 plis
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Ap rekriteFaz 3
- Yale New Haven Hospital, New Haven
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Ap rekriteFaz 2
- Yale University, New Haven
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Yale Cancer Center, New Haven
Etid Myelom Miltip nan lòt vil
- New York City, NY60 etid
- Boston, MA42 etid
- Atlanta, GA41 etid
- Houston, TX38 etid
- Durham, NC37 etid
- Nashville, TN32 etid
- Denver, CO27 etid
- Rochester, MN24 etid
- St. Louis, MO24 etid
- Columbus, OH24 etid
- Baldwin Park, CA23 etid
- Chicago, IL22 etid
Lòt etid nan New Haven
- Kansè Poumon ki pa ti selil41 etid
- Kansè nan tete37 etid
- Kansè (tout kalite)33 etid
- Kansè Metastatik23 etid
- Kansè poumon22 etid
- Karsinòm selil skuamèz tèt ak kou22 etid
- Kansè ovè21 etid
- Kansè kolorektal20 etid
- Kansè pwostat20 etid
- Sòvdòz Opioyid18 etid
- Twoub Konsomasyon Alkòl (AUD)17 etid
- Leksemi mieloïd egi17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.